T1	Fact 30 282	The average time to death prior to the development of modern treatment strategies for patients with AAV was 5 months89, yet with advances in treatment, mortality rates have significantly improved with recent data for 1 year mortality reported as 11%90.
A1	Source T1 Non-integral_information_led_citation
A2	Multiple_sources T1
T2	KT_cue 30 137	The average time to death prior to the development of modern treatment strategies for patients with AAV was
R1	Cue Arg1:T2 Arg2:T1	
T3	Source_cue 146 149	89,
R2	Cue Arg1:T3 Arg2:T1	
T4	Source_cue 279 282	90.
R3	Cue Arg1:T4 Arg2:T1	
T5	Observation 283 387	Historically, reported outcomes for this patient group was largely confined to single-centre experience.
A3	Source T5 Averred
T6	KT_cue 297 341	reported outcomes for this patient group was
R4	Cue Arg1:T6 Arg2:T5	
T7	Fact 388 564	However, in more recent years collaboration between centres on a national and international level has allowed for wider experience, with larger patient numbers to be published.
A4	Source T7 Averred
T8	KT_cue 418 501	collaboration between centres on a national and international level has allowed for
R5	Cue Arg1:T8 Arg2:T7	
T9	Investigation 566 728	The first of these by the "Pan- Thames" group included patients presenting to 7 London hospitals with a new diagnosis of renal vasculitis between 1995 and 200091.
A5	Source T9 Non-integral_information_led_citation
T10	KT_cue 566 620	The first of these by the "Pan- Thames" group included
R6	Cue Arg1:T10 Arg2:T9	
T11	Source_cue 725 728	91.
R7	Cue Arg1:T11 Arg2:T9	
T12	Investigation 729 826	313 patients were included with the majority having a diagnosis of MPA 120 (49%) or GPA 82 (33%).
A6	Citation_length T12 Extended
A7	Source T12 Non-integral_information_led_citation
T13	KT_cue 729 755	313 patients were included
R8	Cue Arg1:T13 Arg2:T12	
T14	Observation 	
A8	Citation_length T14 Extended
A9	Source T14 Non-integral_information_led_citation
T15	Observation 827 889	Survival rates at 1 and 5 years were 84% and 76% respectively.
A10	Citation_length T15 Extended
A11	Source T15 Non-integral_information_led_citation
T16	KT_cue 827 863	Survival rates at 1 and 5 years were
R9	Cue Arg1:T16 Arg2:T15	
T17	Investigation 890 1093	Predictors for mortality were poorer renal function at presentation (with those presenting with end stage renal failure having a 5-year survival of 53%, p= 0.01) and age greater than 60 years (p=0.0002).
A12	Citation_length T17 Extended
A13	Source T17 Non-integral_information_led_citation
T18	KT_cue 890 919	Predictors for mortality were
R10	Cue Arg1:T18 Arg2:T17	
T19	Observation 1094 1223	Infection and leucopenia were the most common adverse events, with treatment induced leucopenia occurring in 99 (41%) of patients
A14	Citation_length T19 Extended
A15	Source T19 Non-integral_information_led_citation
T20	KT_cue 1124 1155	the most common adverse events,
R11	Cue Arg1:T20 Arg2:T19	
T21	Analysis 1224 1277	and being strongly associated with sepsis (p< 0.001).
A16	Source T21 Non-integral_information_led_citation
A17	Citation_length T21 Extended
A18	Certainty_Level T21 L2
T22	KT_cue 1234 1253	strongly associated
R12	Cue Arg1:T22 Arg2:T21	
T23	CL_cue 1234 1253	strongly associated
R13	Cue Arg1:T23 Arg2:T21	
T24	Analysis 1278 1626	Seventy- three episodes of sepsis were reported (although it is not stated in how many patients they occurred), the presence of which were a predictor of mortality (p= 0.048) with the most common infection being pneumonia at 23 episodes (31.5%), followed by neutropenic sepsis at 12 episodes (16.4%) then herpes zoster virus at 11 episodes (15.1%).
A19	Citation_length T24 Extended
A20	Source T24 Non-integral_information_led_citation
T25	KT_cue 1278 1325	Seventy- three episodes of sepsis were reported
R14	Cue Arg1:T25 Arg2:T24	
A21	Certainty_Level T24 L4
T26	CL_cue 1278 1325	Seventy- three episodes of sepsis were reported
R15	Cue Arg1:T26 Arg2:T24	
T27	KT_other 1627 1650	It should be noted that
A22	Source T27 Averred
A23	Verb_noun T27 Verb_noun_other
A24	Modality T27
T28	KT_cue 1627 1645	It should be noted
R16	Cue Arg1:T28 Arg2:T27	
T29	Verb_cue 1627 1650	It should be noted that
R17	Cue Arg1:T29 Arg2:T27	
T30	Investigation 1651 1708	this study only included patients with renal involvement,
A25	Source T30 Averred
T31	KT_cue 1651 1675	this study only included
R18	Cue Arg1:T31 Arg2:T30	
T32	Analysis 1709 1803	and therefore this is likely to have had an impact upon mortality and possibly adverse events.
A26	Source T32 Averred
A27	Certainty_Level T32 L2
T33	KT_cue 1713 1722	therefore
R19	Cue Arg1:T33 Arg2:T32	
T34	CL_cue 1731 1740	likely to
R20	Cue Arg1:T34 Arg2:T32	
T35	Investigation 1804 1963	There was no mention of adjustment of cyclophosphamide dose for renal function, but the majority of centres used oral therapy, compared with intravenous (2/7).
A28	Citation_length T35 Extended
A29	Source T35 Non-integral_information_led_citation
T36	KT_cue 1804 1838	There was no mention of adjustment
R21	Cue Arg1:T36 Arg2:T35	
A30	Neg_CL T35
T37	Investigation 1964 2182	Similarly, the French Vasculitis Group retrospectively analysed 595 patients with a diagnosis of MPA, Eosinophilic Granulomatosis with Polyangiitis or Polyarteritis Nodosa diagnosed and treated between 1953 and 199992.
A31	Source T37 Non-integral_information_led_citation
T38	KT_cue 1975 2027	the French Vasculitis Group retrospectively analysed
R22	Cue Arg1:T38 Arg2:T37	
T39	Source_cue 2179 2181	92
R23	Cue Arg1:T39 Arg2:T37	
T40	Observation 2183 2329	60 patients (10%) died in the first year following diagnosis with 33 (55%) of these deaths related to active vasculitis and 27 (45%) to infection.
A32	Citation_length T40 Extended
A33	Source T40 Non-integral_information_led_citation
T41	KT_cue 2183 2205	60 patients (10%) died
R24	Cue Arg1:T41 Arg2:T40	
T42	Observation 2330 2448	They also found that older age, renal involvement, and central nervous system involvement was predictive of mortality.
A34	Citation_length T42 Extended
A35	Source T42 Non-integral_information_led_citation
T43	KT_cue 2330 2345	They also found
R25	Cue Arg1:T43 Arg2:T42	
A36	Verb_noun T42 Certainty
T44	Verb_cue 2330 2350	They also found that
R26	Cue Arg1:T44 Arg2:T42	
T45	Analysis 2449 2628	Of note in this study is the extensive time period from which these patients were recruited, meaning that therapy was variable depending on the era in which patients were treated.
A37	Source T45 Averred
A38	Certainty_Level T45 L4
T46	KT_cue 2449 2456	Of note
R27	Cue Arg1:T46 Arg2:T45	
T47	CL_cue 2449 2456	Of note
R28	Cue Arg1:T47 Arg2:T45	
T48	Analysis 2629 2783	Analysis by time of diagnosis showed that mortality has improved significantly since 1990, compared with patients presenting prior to this date (p< 0.01).
A39	Source T48 General_reference
A40	Verb_noun T48 Certainty
A41	Certainty_Level T48 L4
T49	KT_cue 2629 2665	Analysis by time of diagnosis showed
R29	Cue Arg1:T49 Arg2:T48	
T50	CL_cue 2629 2665	Analysis by time of diagnosis showed
R30	Cue Arg1:T50 Arg2:T48	
T51	Verb_cue 2629 2670	Analysis by time of diagnosis showed that
R31	Cue Arg1:T51 Arg2:T48	
T52	Source_cue 2708 2719	since 1990,
R32	Cue Arg1:T52 Arg2:T48	
T53	Fact 2785 2970	In 2007 the European League Against Rheumatism (EULAR) Systemic Vasculitis Task Force also published a systematic review of outcome data from patients with AAV that included 44 studies.
A42	Source T53 Other_citation
T54	KT_cue 2785 2885	In 2007 the European League Against Rheumatism (EULAR) Systemic Vasculitis Task Force also published
R33	Cue Arg1:T54 Arg2:T53	
T55	Source_cue 2785 2870	In 2007 the European League Against Rheumatism (EULAR) Systemic Vasculitis Task Force
R34	Cue Arg1:T55 Arg2:T53	
T56	Analysis 2971 3059	They reported 1-year survival rates of 85-97% in GPA, 82-92% in MPA and 93- 94% in EGPA.
A43	Source T56 Other_citation
A44	Citation_length T56 Extended
A45	Certainty_Level T56 L4
T57	KT_cue 2971 2984	They reported
R35	Cue Arg1:T57 Arg2:T56	
T58	CL_cue 2971 2984	They reported
R36	Cue Arg1:T58 Arg2:T56	
T59	Observation 3060 3153	Five- year survival rates were only available for patients with GPA and reported as 75-88%93.
A46	Citation_length T59 Extended
A47	Source T59 Non-integral_information_led_citation
T60	KT_cue 3060 3090	Five- year survival rates were
R37	Cue Arg1:T60 Arg2:T59	
T61	Source_cue 3150 3153	93.
R38	Cue Arg1:T61 Arg2:T59	
T62	Observation 3154 3302	Age and renal function were found once again to predict mortality but also the presence of damage, as measured by the Vasculitis Damage Index (VDI).
A48	Citation_length T62 Extended
A49	Source T62 Non-integral_information_led_citation
T63	KT_cue 3154 3187	Age and renal function were found
R39	Cue Arg1:T63 Arg2:T62	
T64	Fact 3303 3445	The VDI is a validated assessment tool which records damage accrued not only due to vasculitis, but also due to treatment for the condition94.
A50	Source T64 Non-integral_information_led_citation
T65	KT_cue 3303 3313	The VDI is
R40	Cue Arg1:T65 Arg2:T64	
T66	Source_cue 3442 3445	94.
R41	Cue Arg1:T66 Arg2:T64	
T67	Investigation 3447 3772	In recent years, the European Vasculitis Study Group (EUVAS) have completed a number of randomised controlled trials in patients with AAV to answer questions with regards to the efficacy of specific therapeutic options; CYCLOPS74, NORAM95, CYCAZAREM96, MEPEX73 and IMPROVE97 in addition to the Rituximab study outlined above.
A51	Source T67 Other_citation
T68	KT_cue 3464 3522	the European Vasculitis Study Group (EUVAS) have completed
R42	Cue Arg1:T68 Arg2:T67	
T69	Source_cue 3464 3507	the European Vasculitis Study Group (EUVAS)
R43	Cue Arg1:T69 Arg2:T67	
T70	Observation 3773 3918	A combined review of outcomes for the first 4 of these studies has provided follow- up data for a median duration of 5.2 years in 535 patients98.
A52	Source T70 Non-integral_information_led_citation
T71	KT_cue 3773 3848	A combined review of outcomes for the first 4 of these studies has provided
R44	Cue Arg1:T71 Arg2:T70	
T72	Source_cue 3915 3918	98.
R45	Cue Arg1:T72 Arg2:T70	
T73	Fact 3919 3980;3981 4074	The leading cause of death in the first year was infection at 47.5 % of deaths followed by active vasculitis at 18.6% then cardiovascular disease at 15.3%.
A53	Citation_length T73 Extended
A54	Source T73 Non-integral_information_led_citation
T74	KT_cue 3919 3967	The leading cause of death in the first year was
R46	Cue Arg1:T74 Arg2:T73	
T75	Fact 4075 4255	After the first year, cardiovascular disease became the commonest cause of death at 25.7% followed by malignancy at 21.6%, with infection still contributing significantly at 20.3%.
A55	Citation_length T75 Extended
A56	Source T75 Non-integral_information_led_citation
T76	KT_cue 4097 4126	cardiovascular disease became
R47	Cue Arg1:T76 Arg2:T75	
T77	Fact 4256 4473	Significant predictors of mortality were the presence of both MPO and PR3 ANCA (dual positivity), age greater than 75 years and estimated glomerular filtration rate (eGFR) < 15mls/min (chronic kidney disease stage 5).
A57	Citation_length T77 Extended
A58	Source T77 Non-integral_information_led_citation
T78	KT_cue 4256 4296	Significant predictors of mortality were
R48	Cue Arg1:T78 Arg2:T77	
T79	Investigation 4474 4624	There is currently data collection underway for the 10 year follow- up for this study which will provide more valuable long-term data for this cohort.
A59	Source T79 Other_citation
T80	KT_cue 4474 4517	There is currently data collection underway
R49	Cue Arg1:T80 Arg2:T79	
T81	Fact 4626 4797	Specific to those patients with renal involvement, the Chapel Hill group has recently published outcomes for 554 patients with AAV with a median follow- up of 31 months99.
A60	Source T81 Non-integral_information_led_citation
T82	KT_cue 4677 4721	the Chapel Hill group has recently published
R50	Cue Arg1:T82 Arg2:T81	
T83	Source_cue 4677 4698;4794 4797	the Chapel Hill group 99.
R51	Cue Arg1:T83 Arg2:T81	
T84	Analysis 4797 5065	This study, encompassing outcomes for patients diagnosed between 1985 and 2009, reported that renal function at diagnosis has improved over time; patients having a median eGFR of 11 ml/min/1.73 m2 in the earliest time period and 23 ml/min/1.73 m2 in the latest period.
A61	Verb_noun T84 Speech_act_communication
A62	Source T84 Non-integral_information_led_citation
T85	Source_cue 4797 4808	This study,
R52	Cue Arg1:T85 Arg2:T84	
T86	KT_cue 4797 4808;4877 4885	This study, reported
R53	Cue Arg1:T86 Arg2:T84	
T87	CL_cue 4797 4808;4877 4885	This study, reported
R54	Cue Arg1:T87 Arg2:T84	
T88	Verb_cue 4797 4808;4877 4890	This study, reported that
R55	Cue Arg1:T88 Arg2:T84	
T89	Analysis 5066 5105	This would explain the observation that
A64	Verb_noun T89 Certainty
A65	Source T89 Hidden
A66	Certainty_Level T89 L1
T90	KT_cue 5066 5084	This would explain
R56	Cue Arg1:T90 Arg2:T89	
T91	CL_cue 5066 5084	This would explain
R57	Cue Arg1:T91 Arg2:T89	
T92	Modality_cue 5066 5084	This would explain
R58	Cue Arg1:T92 Arg2:T89	
T93	Source_cue 5066 5084	This would explain
R59	Cue Arg1:T93 Arg2:T89	
T94	Verb_cue 5085 5105	the observation that
R60	Cue Arg1:T94 Arg2:T89	
T95	Observation 5106 5160	significantly fewer patients developed ESRD over time.
A67	Source T95 Non-integral_information_led_citation
A68	Citation_length T95 Extended
T96	KT_cue 5106 5144	significantly fewer patients developed
R61	Cue Arg1:T96 Arg2:T95	
T97	Observation 5161 5349	There was no significant difference in the adjusted relapse rate over time with no factors identified associated with relapse (including ANCA type or duration of cyclophosphamide therapy).
A69	Citation_length T97 Extended
A70	Source T97 Non-integral_information_led_citation
A71	Neg_CL T97
T98	KT_cue 5161 5170	There was
R62	Cue Arg1:T98 Arg2:T97	
T99	Analysis 5350 5566	The authors suggested that this may be due to the inclusion of only those with renal involvement having received cyclophosphamide, therefore excluding many patients perhaps with airway limited PR3 associated disease.
A63	Modality T99
A72	Source T99 Non-integral_information_led_citation
A73	Verb_noun T99 Speech_act_communication
A74	Citation_length T99 Extended
A75	Certainty_Level T99 L1
T100	KT_cue 5350 5371	The authors suggested
R63	Cue Arg1:T100 Arg2:T99	
T101	CL_cue 5350 5371	The authors suggested
R64	Cue Arg1:T101 Arg2:T99	
T102	Verb_cue 5350 5376	The authors suggested that
R65	Cue Arg1:T102 Arg2:T99	
T103	Modality_cue 5377 5388	this may be
R66	Cue Arg1:T103 Arg2:T99	
T104	Analysis 5567 5792	Data from other  sources additionally supports that generally outcomes from AAV are improving with a decline in Standardised Mortality Ratios from 2.1 to 1.03, in subsequent German vasculitis cohorts over a 36 years period64.
A76	Source T104 Non-integral_information_led_citation
A77	Certainty_Level T104 L2
T105	KT_cue 5619 5628	generally
R67	Cue Arg1:T105 Arg2:T104	
T106	CL_cue 5619 5628	generally
R68	Cue Arg1:T106 Arg2:T104	
T107	Source_cue 5789 5792	64.
R69	Cue Arg1:T107 Arg2:T104	
T108	Analysis 5793 5864	However, it is clear that morbidity from treatment is still significant
A78	Source T108 Averred
A79	Certainty_Level T108 L3
T109	KT_cue 5802 5813	it is clear
R70	Cue Arg1:T109 Arg2:T108	
T110	CL_cue 5802 5813	it is clear
R71	Cue Arg1:T110 Arg2:T108	
T111	Investigation 5865 5945	and ways of approaching prevention of this shall be addressed in later sections.
A80	Source T111 Self_other
T112	KT_cue 5869 5945	ways of approaching prevention of this shall be addressed in later sections.
R72	Cue Arg1:T112 Arg2:T111	
T113	Analysis 5960 6096	The risk of disease relapse for patients with AAV appears to be in the order of 50%100,101(with follow- up over 44 months in 2 cohorts).
A81	Source T113 General_reference
A82	Certainty_Level T113 L1
T114	KT_cue 5960 6023	The risk of disease relapse for patients with AAV appears to be
R73	Cue Arg1:T114 Arg2:T113	
T115	CL_cue 5960 6023	The risk of disease relapse for patients with AAV appears to be
R74	Cue Arg1:T115 Arg2:T113	
T116	Analysis 6097 6301	One group's reports have suggested that relapse rates may be reducing, with a relapse rate of 35.3% in patients diagnosed from 1999 to 2002, compared with 51.2% of those diagnosed between 1994 and 199864.
A83	Verb_noun T116 Speech_act_communication
A84	Source T116 Non-integral_information_led_citation
A85	Modality T116
A86	Certainty_Level T116 L1
T117	Verb_cue 6097 6136	One group's reports have suggested that
R75	Cue Arg1:T117 Arg2:T116	
T118	KT_cue 6097 6131	One group's reports have suggested
R76	Cue Arg1:T118 Arg2:T116	
T119	CL_cue 6097 6131	One group's reports have suggested
R77	Cue Arg1:T119 Arg2:T116	
T120	Modality_cue 6137 6167	relapse rates may be reducing,
R78	Cue Arg1:T120 Arg2:T116	
T121	Source_cue 6097 6116;6298 6301	One group's reports 64.
R79	Cue Arg1:T121 Arg2:T116	
T122	Analysis 6302 6441	As mentioned above, however, the Chapel Hill study did not report an improvement in relapse rates with their 5-year relapse rate being 35%.
A87	Source T122 Other_citation
A88	Neg_CL T122
A89	Certainty_Level T122 L4
T123	Source_cue 6302 6352	As mentioned above, however, the Chapel Hill study
R80	Cue Arg1:T123 Arg2:T122	
T124	KT_cue 6331 6367	the Chapel Hill study did not report
R81	Cue Arg1:T124 Arg2:T122	
T126	CL_cue 6331 6367	the Chapel Hill study did not report
T125	Observation 6442 6519	Furthermore, longer term follow-up data from the CYCLOPS trial has shown that
A90	Verb_noun T125 Certainty
T127	KT_cue 6455 6514	longer term follow-up data from the CYCLOPS trial has shown
R82	Cue Arg1:T127 Arg2:T125	
T128	Verb_cue 6455 6519	longer term follow-up data from the CYCLOPS trial has shown that
R83	Cue Arg1:T128 Arg2:T125	
A91	Source T125 Non-integral_information_led_citation
T129	Source_cue 6487 6504;6740 6743	the CYCLOPS trial 75.
R84	Cue Arg1:T129 Arg2:T125	
T130	Analysis 6520 6743	those treated with pulsed i.v. therapy were significantly more likely to have relapsed at follow-up (median duration 4.3 years) but this was not associated with a difference in mortality or morbidity between the two arms75.
A92	Source T130 Non-integral_information_led_citation
A93	Certainty_Level T130 L2
T131	KT_cue 6564 6592	significantly more likely to
R85	Cue Arg1:T131 Arg2:T130	
T132	CL_cue 6564 6592	significantly more likely to
R86	Cue Arg1:T132 Arg2:T130	
T133	Observation 6744 6997	Other studies have shown the pattern of organ involvement to help predict relapse risk with respiratory involvement, cardiac involvement and lack of significant renal involvement (creatinine clearance >60ml/min) all being risk factors for relapse93,101.
A94	Source T133 Non-integral_information_led_citation
T134	Source_cue 6744 6757;6990 6997	Other studies 93,101.
R87	Cue Arg1:T134 Arg2:T133	
T135	KT_cue 6744 6768	Other studies have shown
R88	Cue Arg1:T135 Arg2:T133	
T136	Analysis 6998 7082	PR3 positivity has been recurrently demonstrated to be a risk factor for relapse102,
A95	Source T136 Non-integral_information_led_citation
A96	Certainty_Level T136 L4
T137	KT_cue 6998 7049	PR3 positivity has been recurrently demonstrated to
R89	Cue Arg1:T137 Arg2:T136	
T138	CL_cue 6998 7049	PR3 positivity has been recurrently demonstrated to
R90	Cue Arg1:T138 Arg2:T136	
T139	Source_cue 7078 7082	102,
R91	Cue Arg1:T139 Arg2:T136	
T140	Fact 7083 7151	however, the relationship between ANCA titres and relapse is complex
A97	Source T140 Averred
T141	KT_cue 7092 7151	the relationship between ANCA titres and relapse is complex
R92	Cue Arg1:T141 Arg2:T140	
T142	Investigation 7152 7190	and is discussed in more detail below.
A98	Source T142 Self_other
T143	KT_cue 7156 7190	is discussed in more detail below.
R93	Cue Arg1:T143 Arg2:T142	
T144	Observation 7192 7382	Nasal carriage of Staph.aureus has been shown to be associated with a higher rate of disease relapse47 with treatment with co-trimoxazole shown to be efficacious in reducing relapse rates48.
A99	Source T144 Non-integral_information_led_citation
A100	Multiple_sources T144
T145	KT_cue 7192 7240	Nasal carriage of Staph.aureus has been shown to
R94	Cue Arg1:T145 Arg2:T144	
T146	Source_cue 7292 7294	47
R95	Cue Arg1:T146 Arg2:T144	
T147	Source_cue 7379 7382	48.
R96	Cue Arg1:T147 Arg2:T144	
T148	Analysis 7383 7451	The mechanism behind this association is not as yet fully understood
A101	Source T148 Averred
A102	Certainty_Level T148 L3
T149	KT_cue 7383 7451	The mechanism behind this association is not as yet fully understood
R97	Cue Arg1:T148 Arg2:T149	
T150	CL_cue 7383 7451	The mechanism behind this association is not as yet fully understood
R98	Cue Arg1:T150 Arg2:T148	
T151	Analysis 7452 7584	with roles for molecular mimicry, Toll Like receptors and Neutrophil Extracellular Traps all suggested as potential explanations103.
A103	Source T151 Non-integral_information_led_citation
A104	Certainty_Level T151 L1
T152	KT_cue 7545 7557	suggested as
R99	Cue Arg1:T152 Arg2:T151	
T153	CL_cue 7545 7557	suggested as
R100	Cue Arg1:T153 Arg2:T151	
T154	Source_cue 7580 7584	103.
R101	Cue Arg1:T154 Arg2:T151	
